Bayer HealthCare and Ortho-McNeil Pharmaceutical entered into license agreement to jointly develop and market Factor Xa inhibitor BAY 59-7939 which is in phase 2 clinical trials for preventing and treating thrombosis. The analyst opinion article states that this deal offers J&J to boost itself in the areas of cardiovascular diseases and also has fed Bayer’s ambition to focus on its speciality business. However, the analyst questions about the long-term suitability of J&J as a partner for BAY 59-1939.